The U.S. Intravenous Solutions Market, estimated at USD 3,644.0 Mn in 2025, is expected to exhibit a CAGR of 7.2% and reach USD 5,928.5 Mn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
Key market players are focusing on adopting growth strategies such as agreements, which will drive the U.S. intravenous solutions market. For instance, in April 2025, ICU Medical, Inc., one of the global leaders in the development, manufacture, and sale of innovative medical devices used in infusion therapy and critical care applications, and Scripps Health, one of the leading health systems in the western U.S., announced that they had signed a long-term purchase agreement covering ICU Medical’s full line of IV solutions and consumables, along with the Plum 360 infusion system and ICU Medical MedNet IV medication safety software.
U.S. Intravenous Solutions Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of things from one place to another.
COVID-19 had a positive impact on the U.S. intravenous solutions market. Increasing demand for intravenous solutions in COVID-19 is expected to drive the growth of the U.S. intravenous solutions market. For instance, in August 2025, UNICEF, a humanitarian aid organization responsible for providing humanitarian and developmental aid to children worldwide, published data according to which global supply chains and the procurement of essential medical goods, including IV solutions, were under unheard-of pressure as a result of the COVID-19 epidemic. This contains intravenous solutions, which can help newborn children and COVID-19 patients around the world. People who have COVID-19 and other illnesses, such as severe pneumonia and diarrhea, can greatly benefit from the intravenous solutions.
U.S. Intravenous Solutions Market: Key Developments
On August 8, 2025, Monidor, a health technology company specializing in remote monitoring, announced the expansion of its remote monitoring of IV therapy in collaboration with B. Braun Medical Inc., a international medical device manufacturer.
In May 2025, Fresenius Kabi, one of the global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, announced the acquisition of Ivenix, Inc., a specialized intravenous therapy company.
In September 2025, Baxter International Inc., one of the leading global medical products companies, announced that it had entered into an agreement to acquire Cheetah Medical, one of the leading providers of non-invasive hemodynamic monitoring technologies. Cheetah Medical is a logical adjacency for Baxter given that it has long been a pioneer in intravenous (IV) solutions and infusion systems, has extensive knowledge in fluid management, and has a sizeable presence in critical care and IV therapy.
Browse 15 Market Data Tables and 46 Figures spread through 120 Pages and in-depth TOC on “U.S. Intravenous Solutions Market”- Forecast to 2032, U.S. Intravenous Solutions Market, By Solution Type (Saline (Normal saline 0.9% NaCl and Hypertonic saline), Dextran (D5W 5% dextrose in water and Analog Hypertonic Saline), Lactated Ringer’s, Amino Acid, Vitamins & Minerals, Heparin and trace elements, and Mixed Solutions), By Packaging (Ampules, Vials, Cartridges, Bottles, and Bags (Large Volume Bags-greater than 250ml and Small Volume Bags-less than 250ml), By Application (Basic IV Solution, Nutritional IV Solution, Blood IV Solution, Drug IV Solution, Irrigation IV Solution),and By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home care Settings, and Others).
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/us-intravenous-solution-market-3400
Key Takeaways of the U.S. Intravenous Solutions Market:
- The U.S. intravenous solutions market is expected to exhibit a CAGR of 7.2% during the forecast period.
- Among solution type, the lactated ringer’s segment is expected to hold a dominant position in the U.S. intravenous solutions market during the forecast period, and this is attributed to inorganic strategies such as facility expansion by key players. For instance, in August 2025, Henry Schein, Inc., one of the leading manufacturers of lactated ringer’s, announced an increase in credit facilities in the U.S.
- Major players operating in the U.S. intravenous solutions market are Baxter International Inc., ICU Medical, Inc., Braun Melsungen Ag, and Grifols, S.A.
Contact Us